)
Research & Development
Innovation is in Our DNA
Innovation is in our DNA and is the core of everything we do at CSL Behring. Our team of over 1,700 R&D experts are dedicated to developing and delivering new therapies to solve unmet medical needs and save lives. We have created one of the largest and most efficient plasma collection networks in the world and strive to be the best at delivering safe and effective medicines for our patients.
-
US $832 million
was invested in R&D in 2018/19 (incl. Seqirus)
-
US $3.3 billion
in R&D investments in the last 5 years (incl. Seqirus)
-
>1,700
research & development employees
Investment in our R&D
Investment in R&D is an important driver for CSL Behring’s future growth. We have a high quality and potentially valuable portfolio of projects in various stages of development. We continue to make a balanced investment in the life cycle management and market development of existing products that bring short to mid-term commercial benefits, and we make strategic investments in longer term, higher risk and high opportunity new product development activities.
Find a Clinical Trial
A clinical trial is a research study that is done to find out if medical treatments can improve people’s health. A medical treatment can be a drug, medical device, medical procedure, or a change in a person’s behavior such as diet or exercise. People who take part in clinical trials are volunteers. They are also called “participants."
| Therapeutic Area | Condition | Description | |
| Haematology and Thrombosis |
Hemophilia A | CSL627_3001: An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A. | Learn More |
| Hemophilia B | CSL654_3003: A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B | Learn More | |
| Hemophilia A & B | CSL689_2001: Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors | Terminated | |
| Congenital Fibrinogen Deficiency | BI3023_4003: An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency | Completed | |
| Von Willebrand Disease | CSLCT-BIO-12-83: Study of Voncento® in Subjects With Von Willebrand Disease | Completed | |
| Reversal of acquired coagulation factor deficiency | BE1116_4001: An Observational Cohort Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra® or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding | Learn More | |
| Sickle Cell | CSL200_1001: CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease | Learn More | |
| Cardiovascular and Metabolic | Acute Coronary Syndrome | CSL112_3001: Study to investigate CSL112 in Subjects With Acute Coronary Syndrome (AEGIS-II) | Learn More |
| Coronary Heart Disease | CSL112_1001: Assessing the pharmacokinetics, safety, and tolerability of CSL112 in healthy Japanese and Caucasian adults | Completed | |
| Immunology and Neurology | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | IgPro20_3004: Extension Study of Maintenance Treatment with Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Results |
| Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | IgPro10_5004: Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP (HELIPAD 1) | Learn More | |
| Dermatomyositis (DM) | IgPro20_3007: A study to evaluate the efficacy, safety, and pharmacokinetics of IgPro20 in adults with Dermatomyositis (DM) | Learn More | |
| Pediatric CIDP | IgPro10_4002: Randomized Study of Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP | Learn More | |
| Hereditary Angioedema (HAE) | CSL312_2001: A study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE) | Learn More | |
| Primary Immune Deficiency (PID) | IgPro20_4004: Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra®) in Subjects With Primary Immunodeficiency (PID) | Completed | |
| Primary Immune Deficiency (PID) | IgPro20_4005: Study of Immune Deficiency Patients treated with Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly Schedules | Results | |
| Primary Immune Deficiency (PID) | IgPro20_1001: Comparison of 2 Infusion Devices With Respect to Pharmacokinetics, Safety, and Tolerability of Hizentra: An Investigational Wearable Infusor and the Crono S-PID-50 Infusion Pump | Learn More | |
| Healthy Subjects | CSL730_1001: Assessing the Safety and Tolerability of CSL730 in Healthy Caucasian and Japanese Adults | Learn More | |
| Healthy Subjects | CSL324_1001: Dose escalation, placebo-controlled phase 1 study to assess the safety and tolerability of CSL324 in healthy adults | Completed | |
| Respiratory | Mild Asthma | CSL311_1001: A Clinical Study to test the safety, exposure, and markers of Efficacy of CSL311 in patients with mild asthma. | Learn More |
| Transplant | Antibody-mediated kidney transplant rejection | CSL842_3001: Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients | Learn More |
| Acute GVHD (aGVHD) | CSL964_2001: The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft‑Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant (MODULAATE) | Learn More |
World-Class R&D Network
CSL is a global specialty biotech with a strong commitment to funding research and development of medicines to support its continued growth. We operate as one integrated global research and development organization that assembles coordinated global project teams, drawing together staff from different countries depending on their expertise. Our teams rely on a project management framework that facilitates collaboration across national and cultural boundaries.
Australia
PARKVILLE, VIC
CSL Limited
Global Corporate HQ
R&D and Manufacturing
BROADMEADOWS, VIC
CSL Behring
R&D and Manufacturing
NORTH MELBOURNE, VIC
Bio21 Global Research and Translational Medicine Hub
Germany
MARBURG
CSL Behring
R&D and Manufacturing
United States
KING OF PRUSSIA, PA
CSL Behring
Head Office and R&D
KANKAKEE, IL
CSL Behring
R&D and Manufacturing
PASADENA, CA
Calimmune
R&D
Switzerland
BERN
CSL Behring
R&D and Manufacturing
Japan
TOKYO
CSL Behring
R&D
China
WUHAN
Ruide
R&D and Manufacturing